EA201790871A1 - Нацеленные конъюгатные композиции xten и способы их получения - Google Patents
Нацеленные конъюгатные композиции xten и способы их полученияInfo
- Publication number
- EA201790871A1 EA201790871A1 EA201790871A EA201790871A EA201790871A1 EA 201790871 A1 EA201790871 A1 EA 201790871A1 EA 201790871 A EA201790871 A EA 201790871A EA 201790871 A EA201790871 A EA 201790871A EA 201790871 A1 EA201790871 A1 EA 201790871A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- compositions
- conjugate compositions
- xten
- tared
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Abstract
Согласно настоящему изобретению предложены лекарственные конъюгатные композиции и композиции и способы их получения. В некоторых воплощениях настоящее изобретение относится к нацеленным конъюгатным композициям, содержащим цистеин-содержащие домены (CCD), связанные с нацеливающими группировками, удлиненные рекомбинантные полипептиды (XTEN) и расщепляемые пептидные группировки, с фармакологически активными лекарственными средствами в качестве полезной нагрузки, перекрестно-связанными с цистеиновыми остатками, т.е. к композициям, которые могут расщепляться протеазами, ассоциированными с тканями-мишенями. Согласно изобретению предложены также способы получения этих нацеленных конъюгатных композиций и способы использования этих нацеленных конъюгатных композиций.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462078171P | 2014-11-11 | 2014-11-11 | |
US201562119483P | 2015-02-23 | 2015-02-23 | |
US201562211378P | 2015-08-28 | 2015-08-28 | |
PCT/US2015/060230 WO2016077505A2 (en) | 2014-11-11 | 2015-11-11 | Targeted xten conjugate compositions and methods of making same |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201790871A1 true EA201790871A1 (ru) | 2017-11-30 |
Family
ID=55955256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201790871A EA201790871A1 (ru) | 2014-11-11 | 2015-11-11 | Нацеленные конъюгатные композиции xten и способы их получения |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180125988A1 (ru) |
EP (1) | EP3218390A4 (ru) |
JP (1) | JP2018500049A (ru) |
KR (1) | KR20170083095A (ru) |
CN (1) | CN107207564A (ru) |
AU (1) | AU2015346330A1 (ru) |
BR (1) | BR112017009951A2 (ru) |
CA (1) | CA2964968A1 (ru) |
EA (1) | EA201790871A1 (ru) |
IL (1) | IL251823A0 (ru) |
MX (1) | MX2017006016A (ru) |
PH (1) | PH12017500866A1 (ru) |
SG (1) | SG11201703803WA (ru) |
WO (1) | WO2016077505A2 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2787617C2 (ru) * | 2019-08-07 | 2023-01-11 | Мабплекс Интернешнал Ко., Лтд. | Конъюгаты антитело-лекарственное средство и их применение |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL307276A (en) | 2015-08-28 | 2023-11-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
CR20180453A (es) * | 2016-03-22 | 2018-12-05 | Hoffmann La Roche | Moleculas biespecíficas de células t activadas por proteasas |
ES2947230T3 (es) | 2016-03-22 | 2023-08-03 | Hoffmann La Roche | Moléculas biespecíficas para linfocitos T activadas por proteasa |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
SG11201811290VA (en) | 2016-06-17 | 2019-01-30 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117+cells |
CN110177875B (zh) | 2016-11-28 | 2023-11-28 | 中外制药株式会社 | 包含抗原结合结构域和运送部分的多肽 |
PL3558391T3 (pl) | 2016-12-23 | 2022-05-16 | Immunogen, Inc. | Immunokoniugaty skierowane wobec białka adam9 i sposoby ich stosowania |
EP3558368A4 (en) | 2016-12-23 | 2020-12-30 | MacroGenics, Inc. | ADAM9 BINDING MOLECULES AND THEIR METHODS FOR USE |
WO2018134787A2 (en) | 2017-01-20 | 2018-07-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
KR20190120770A (ko) * | 2017-02-10 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Psma, nkg2d 및 cd16에 결합하는 단백질 |
RU2765997C2 (ru) * | 2017-03-30 | 2022-02-07 | Мерк Патент Гмбх | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования |
WO2018213335A1 (en) * | 2017-05-16 | 2018-11-22 | Scalmibio, Inc. | Activatable antibodies and methods of use thereof |
US20210087548A1 (en) * | 2017-07-24 | 2021-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and Methods for Inducing Protein Function |
US20210206882A1 (en) | 2017-08-01 | 2021-07-08 | Ab Studio Inc. | Bispecific antibodies and uses thereof |
TWI818934B (zh) * | 2017-11-28 | 2023-10-21 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
US20200316233A1 (en) | 2017-11-28 | 2020-10-08 | Board Of Regents Of The University Of Nebraska | Radiopharmaceuticals and methods of use thereof |
JP2021507706A (ja) * | 2017-12-21 | 2021-02-25 | アムニクス ファーマシューティカルズ, インコーポレイテッド | 放出セグメントおよびそれを含む結合組成物 |
CA3103414A1 (en) * | 2018-06-14 | 2019-12-19 | Bioatla, Inc. | Multi-specific antibody constructs |
WO2019246392A1 (en) | 2018-06-22 | 2019-12-26 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
EP3814378A1 (en) | 2018-06-26 | 2021-05-05 | ImmunoGen, Inc. | Immunoconjugates targeting adam9 and methods of use thereof |
TW202011991A (zh) * | 2018-07-18 | 2020-04-01 | 美商建南德克公司 | 用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法 |
CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
MX2021015356A (es) * | 2019-06-11 | 2022-04-06 | Bioatla Inc | Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos. |
CN114041052A (zh) * | 2019-06-26 | 2022-02-11 | 沃特世科技公司 | 具有固定的亲和配体和酶的涂层及其在液相色谱测定中的用途 |
WO2021022678A1 (zh) * | 2019-08-07 | 2021-02-11 | 烟台迈百瑞国际生物医药股份有限公司 | 一种抗体药物偶联物及其应用 |
WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
EP4058466A1 (en) * | 2019-11-13 | 2022-09-21 | Amunix Pharmaceuticals, Inc. | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same |
EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CN115260313B (zh) | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
KR20230041711A (ko) * | 2020-06-25 | 2023-03-24 | 아뮤닉스 파마슈티컬스, 인크. | Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법 |
US11512113B2 (en) | 2020-08-11 | 2022-11-29 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
KR20230083294A (ko) | 2020-09-30 | 2023-06-09 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 폴리펩타이드 접합체 및 사용 방법 |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
TW202237654A (zh) | 2020-12-09 | 2022-10-01 | 美商詹努克斯治療有限公司 | 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法 |
WO2022178754A1 (en) * | 2021-02-25 | 2022-09-01 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates with therapeutic agents and oligonucleotides and uses thereof |
TW202302155A (zh) | 2021-03-08 | 2023-01-16 | 美商伊繆諾金公司 | 用於增加靶向adam9之免疫結合物治療癌症之功效的方法 |
CN117295747A (zh) | 2021-03-23 | 2023-12-26 | 诺维逊生物股份有限公司 | 抗癌核激素受体靶向化合物 |
CN113215195B (zh) * | 2021-04-30 | 2023-04-11 | 四川大学 | 一种在肌源性细胞特异性高表达sia的重组表达载体及其应用 |
EP4347661A1 (en) * | 2021-06-04 | 2024-04-10 | ImmunoGen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
CN114672450B (zh) * | 2022-01-26 | 2022-11-11 | 中山大学附属第一医院 | 一种分离纯化卵泡膜细胞的方法 |
US20240116997A1 (en) | 2022-02-23 | 2024-04-11 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
WO2024020486A2 (en) * | 2022-07-20 | 2024-01-25 | Fuse Biotherapeutics Inc. | Receptor tyrosine kinase-like orphan receptor 1 (ror1)-specific vhh antibodies and multispecific antibodies thereof as immune cell engagers |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7355019B2 (en) * | 2000-06-06 | 2008-04-08 | Sibtech, Inc. | Cysteine-containing peptide tag for site-specific conjugation of proteins |
US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US8383767B2 (en) * | 2008-06-27 | 2013-02-26 | Academia Sinica | Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain |
CN102348715B (zh) * | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
NZ596787A (en) * | 2009-06-08 | 2014-03-28 | Amunix Operating Inc | Growth hormone polypeptides and methods of making and using same |
MX366864B (es) * | 2012-02-27 | 2019-07-26 | Amunix Operating Inc | Composiciones de conjugados de xten y métodos para realizarlas. |
US20130316946A1 (en) * | 2012-05-24 | 2013-11-28 | Cebix, Inc. | Extended recombinant polypeptide-modified c-peptide |
-
2015
- 2015-11-11 KR KR1020177015658A patent/KR20170083095A/ko unknown
- 2015-11-11 BR BR112017009951A patent/BR112017009951A2/pt not_active Application Discontinuation
- 2015-11-11 EA EA201790871A patent/EA201790871A1/ru unknown
- 2015-11-11 SG SG11201703803WA patent/SG11201703803WA/en unknown
- 2015-11-11 CA CA2964968A patent/CA2964968A1/en not_active Abandoned
- 2015-11-11 AU AU2015346330A patent/AU2015346330A1/en not_active Abandoned
- 2015-11-11 US US15/525,819 patent/US20180125988A1/en not_active Abandoned
- 2015-11-11 MX MX2017006016A patent/MX2017006016A/es unknown
- 2015-11-11 JP JP2017544574A patent/JP2018500049A/ja active Pending
- 2015-11-11 CN CN201580073115.6A patent/CN107207564A/zh active Pending
- 2015-11-11 WO PCT/US2015/060230 patent/WO2016077505A2/en active Application Filing
- 2015-11-11 EP EP15858371.6A patent/EP3218390A4/en not_active Withdrawn
-
2017
- 2017-04-20 IL IL251823A patent/IL251823A0/en unknown
- 2017-05-10 PH PH12017500866A patent/PH12017500866A1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2787617C2 (ru) * | 2019-08-07 | 2023-01-11 | Мабплекс Интернешнал Ко., Лтд. | Конъюгаты антитело-лекарственное средство и их применение |
Also Published As
Publication number | Publication date |
---|---|
EP3218390A2 (en) | 2017-09-20 |
CN107207564A (zh) | 2017-09-26 |
KR20170083095A (ko) | 2017-07-17 |
WO2016077505A3 (en) | 2016-07-21 |
AU2015346330A1 (en) | 2017-05-11 |
CA2964968A1 (en) | 2016-05-19 |
BR112017009951A2 (pt) | 2017-12-26 |
MX2017006016A (es) | 2017-06-19 |
JP2018500049A (ja) | 2018-01-11 |
US20180125988A1 (en) | 2018-05-10 |
EP3218390A4 (en) | 2018-11-21 |
WO2016077505A2 (en) | 2016-05-19 |
PH12017500866A1 (en) | 2017-11-06 |
IL251823A0 (en) | 2017-07-31 |
SG11201703803WA (en) | 2017-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201790871A1 (ru) | Нацеленные конъюгатные композиции xten и способы их получения | |
AU2018201441B2 (en) | Xten conjugate compositions and methods of making same | |
TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
MX353608B (es) | Anticuerpo modificado en el que el tema que comprende residuos de cisteina esta ligado, conjugado de farmaco de anticuerpo modificado que comprende el anticuerpo modificado y metodo de produccion para el mismo. | |
MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
MX2017015105A (es) | Compuestos del peptido yy (pyy) selectivos y sus usos. | |
MX2009010148A (es) | Peptidos ciclicos de proteinas receptor-asociadas (rap). | |
PE20130648A1 (es) | Tratamiento del sindrome de sanfilippo tipo b | |
MX2016006053A (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
MX2018005194A (es) | Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas. | |
CL2016001405A1 (es) | A peptide mixture | |
EA201591751A1 (ru) | Трипептидные эпоксикетонные ингибиторы протеазы | |
EA201590705A1 (ru) | ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ | |
EA201170441A1 (ru) | Терапевтические противовирусные пептиды | |
MY167804A (en) | Treatment of degenerative joint disease | |
ECSP10010516A (es) | Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares | |
EA201591752A1 (ru) | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы | |
MY181181A (en) | Fgf21 derivatives and uses thereof | |
EP3501532A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
EA201490901A1 (ru) | Линкеры на основе тирозина для свободного соединения пептидов | |
MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
WO2015024022A3 (en) | Designed peptides for tight junction barrier modulation | |
WO2014039074A3 (en) | Therapeutic compositions and related methods | |
MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. |